Compare
GLP-1 agonists compared
Fifteen compounds act on the GLP-1 receptor. Four are approved, one was discontinued after a liver signal, and the rest are still in trials. Here is what separates them — and where each dose and cycling schedule actually comes from.
Compounds
15
FDA approved
4
In trials
10
Discontinued
1
Last reviewed
25 July 2026
01
Side by side
Every dose and every cycling schedule carries the kind of source it came from. Those are the two columns most comparisons leave out.
| Compound | Receptors | Status | Dose | Source of dose | How often | Route | How it's cycled |
|---|---|---|---|---|---|---|---|
| Semaglutide SEMA | FDA-approved | 0.25 up to 2.4 mg per week (start low, increase slowly) | FDA label | Weekly | Under the skin (also comes as a pill) | Not cycled Peer-reviewed | |
| Tirzepatide TIRZ | FDA-approved | 2.5 up to 15 mg per week (start low, increase slowly) | FDA label | Weekly | Under the skin (subcutaneous) | Not cycled Peer-reviewed | |
| Liraglutide LIRA | FDA-approved | 0.6 up to 3 mg per day (start low, increase slowly) | FDA label | Daily | Under the skin (subcutaneous) | Not cycled FDA label | |
| Orforglipron ORFO | FDA-approved | 0.8 up to 17.2 mg per day (six steps, 30 days apart) | FDA label | Daily | By mouth (oral) | Not cycled in the trials Trial dose | |
| Retatrutide RETA | Investigational | 1 up to 12 mg per dose (start low, increase slowly) | Trial dose | Weekly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| Survodutide SURVO | Investigational | 2.4 up to 6 mg per week (start low, increase slowly) | Trial dose | Weekly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| Mazdutide MAZDU | Investigational | 2 up to 9 mg per dose (start low, increase slowly) | Trial dose | Weekly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| Amycretin AMY | Investigational | 0.3 up to 60 mg per week (start low, increase slowly) | Trial dose | Weekly/daily | By mouth or under the skin | Not cycled in the trials Trial dose | |
| VK2735 VK2735 | Investigational | 2.5 up to 15 mg per week (start low, increase slowly) | Trial dose | Weekly | Under the skin, or by mouth | Not cycled in the trials Trial dose | |
| CagriSema CAGSEM | Investigational | 2.4 mg per week | Trial dose | Weekly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| MariTide (maridebart cafraglutide) MARI | Investigational | 140 up to 420 mg per month (trial doses) | Trial dose | Monthly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| CT-388 CT-388 | Investigational | 4 up to 24 mg per week (trial doses) | Trial dose | Weekly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| Pemvidutide PEMVI | Investigational | 1.2 up to 2.4 mg per week (trial doses) | Trial dose | Weekly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| Zovaglutide (ZT-002) ZOVA | Investigational | 80 up to 160 mg per month (trial doses) | Trial dose | Monthly | Under the skin (subcutaneous) | Not cycled in the trials Trial dose | |
| Danuglipron DANU | Investigational | 40 up to 200 mg per dose | Discontinued | Daily | By mouth (oral) | No schedule. Development stopped in April 2025 Discontinued |
What the table shows
More receptors has meant more weight lost, and more side effects. Semaglutide hits one, tirzepatide two, retatrutide three, and the trial figures rise in that order.
Only four of the fifteen have a dose that comes from a drug label. The rest are trial protocols, which are not the same thing: a trial dose is what researchers chose to test, not what a regulator judged safe for general use.
02
Common questions
Short answers, with the same sourcing rules as the rest of the site.
Which GLP-1 produces the most weight loss?+
In published trials, retatrutide has produced the largest figures, followed by tirzepatide, then semaglutide. Retatrutide is investigational, so those numbers come from trials rather than from years of general use, and nobody yet knows how it behaves over the long run.
What is the difference between Ozempic and Wegovy?+
They are the same drug, semaglutide, approved under two names for two uses. Ozempic is labelled for type 2 diabetes and caps at 2.0 mg a week. Wegovy is labelled for weight management and goes to 2.4 mg.
Is there a GLP-1 pill?+
Yes. Orforglipron is a tablet, approved in April 2026 for weight management. It reaches the same receptor by a different chemical route, which is why it survives digestion where the injected peptides would not. A 25 mg semaglutide tablet was also approved in December 2025.
Why was danuglipron discontinued?+
Pfizer stopped development in April 2025 after a participant showed signs of drug-induced liver injury, which resolved once the drug was withdrawn. It is listed here for reference, not as an option.
Do you regain the weight if you stop?+
In the semaglutide follow-up, people who had lost 17.3% of their body weight regained 11.6 percentage points within a year of stopping, leaving a net loss of 5.6%. That figure is rarely quoted alongside the headline one.